VEGF-responsive promoter-driven adenoviral E1A (VEGF-E1A)

The VEGF-responsive promoter-driven adenoviral E1A is a synthetic genetic construct designed for oncolytic virotherapy, where the expression of the essential viral replication gene E1A is placed under the transcriptional control of the Vascular Endothelial Growth Factor (VEGF) promoter (Zhang et al., 2002, Cancer Research). This configuration exploits the fact that VEGF is significantly upregulated in many solid tumors and their associated vasculature due to hypoxia and oncogenic signaling (Ferrara, 2004, Endocrine Reviews). By linking E1A expression to the VEGF promoter, the adenovirus is engineered to replicate selectively in malignant cells or tumor-associated endothelial cells, leading to targeted cell death and the release of new viral progeny to infect adjacent tumor cells (Hernandez-Alcoceba et al., 2002, Cancer Research). This approach aims to minimize the systemic toxicity typically associated with wild-type adenoviral infections by restricting viral activity to the tumor microenvironment. While promising in preclinical models for various cancers, the strategy faces challenges including the potential for off-target replication in normal tissues undergoing physiological angiogenesis, such as healing wounds or the corpus luteum (Davydova et al., 2004, Gene Therapy). Additionally, the host's innate and adaptive immune responses against the adenoviral vector can limit the duration of the therapeutic effect and the feasibility of repeated dosing.

Other names

VEGF-promoter-E1A constructAd-VEGF-E1AVEGF-regulated E1A expressionVEGF-driven oncolytic adenovirus

Selective expression of the adenoviral E1A gene under the control of a VEGF-responsive promoter, leading to conditional viral replication in VEGF-overexpressing tumor cells.